哮喘预防药物配发对儿童哮喘再入院预防效果的多中心队列链接研究
该多中心队列链接研究纳入2017至2018年因哮喘住院的3-18岁儿童767例,评估出院时哮喘预防药物配发对12个月内再入院的影响。结果显示出院预防药物配发率低且对再入院无保护作用,但社区预防药物配发在保护期内与再入院风险降低相关,学前儿童亚组分析亦显示保护效应。
要点
- 出院时仅26.2%患儿新处方或要求继续使用哮喘预防药物,其中仅45.3%在3天内配发或持有有效处方。
- 出院哮喘预防药物配发对12个月内哮喘再入院无保护作用(OR 1.17,95%CI 0.69-1.97,p=0.57)。
- 社区哮喘预防药物配发在保护期内与再入院风险降低相关(HR 0.61,95%CI 0.36-1.02,p=0.06),学前儿童亚组HR 0.48(95%CI 0.25-0.93,p=0.03)。
核心结论
- 出院时哮喘预防药物处方和配发率低,且对12个月内哮喘再入院无保护作用。
- 社区哮喘预防药物配发在保护期内与再入院风险降低相关,学前儿童亚组分析显示保护效应。
研究设计与样本
- 多中心队列研究,采用链接行政数据,纳入2017至2018年因哮喘住院的3-18岁儿童767例。
主要发现
- 767例中201例(26.2%)出院时新处方或要求继续使用哮喘预防药物,其中仅91例(45.3%)在3天内配发出院处方或持有有效处方。
- 出院哮喘预防药物配发对12个月内再入院无保护作用(OR 1.17,95%CI 0.69-1.97,p=0.57)。
- 566例出院时未处方哮喘预防药物的儿童中,269例(47.5%)在12个月内在社区配发过一次或多次处方。
- 社区哮喘预防药物配发保护期内再入院风险降低(HR 0.61,95%CI 0.36-1.02,p=0.06),学前儿童亚组HR 0.48(95%CI 0.25-0.93,p=0.03)。
临床怎么用
- 应关注出院时哮喘预防药物的处方与配发衔接,提高配发率。
- 社区哮喘预防药物配发可能降低再入院风险,尤其对学前儿童。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To (1) describe the dispensing of asthma preventers at hospital discharge and estimate its effect on hospital readmissions, and (2) estimate the effect of community asthma preventer dispensing on readmissions for the subgroup of children who were not prescribed an asthma preventer at discharge. DESIGN: Multisite cohort study with linked administrative data. PARTICIPANTS: Children aged 3-18 years admitted with asthma to a tertiary paediatric, mixed paediatric and adult, or regional hospital between 2017 and 2018. MAIN OUTCOME MEASURE: Hospital readmission for asthma within 12 months. RESULTS: Of the 767 participants, 201 (26.2%) were newly prescribed or requested to continue with asthma preventers. Of these, only 91 (45.3%) dispensed their discharge prescription within 3 days or had an active prescription. There was no evidence for a protective effect of discharge asthma preventer dispensing on asthma hospital readmissions within 12 months (OR 1.17, 95% CI 0.69 to 1.97, p=0.57). Of the 566 children who were not prescribed asthma preventers at discharge, 269 (47.5%) had one or more prescriptions dispensed in the community within 12 months. Participants who were in the protected period (asthma preventer dispensed) had reduced risk of an asthma hospital readmission (HR 0.61, 95% CI 0.36 to 1.02, p=0.06), including preschool children (HR 0.48, 95% CI 0.25, 0.93, p=0.03) on subgroup analysis. CONCLUSIONS: There was a low rate for prescribing and dispensing of hospital discharge asthma preventers and no protective effect was found for its impact on readmissions. A protective effect on readmissions was found for community asthma preventer dispensing.
引用
- Chen KY, Aye Tun N, Jones R, et al. Effectiveness of asthma preventer dispensing for preventing childhood asthma readmissions: a multisite cohort linkage study. Arch Dis Child. 2023. PMID: 37185082. doi:10.1136/archdischild-2022-324549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。